Fact-checked by Grok 2 weeks ago

Toxoid

A toxoid is a modified bacterial toxin that has been chemically or physically inactivated to eliminate its toxicity while preserving its ability to stimulate an immune response, specifically the production of neutralizing antibodies against the original toxin.^[1] These inactivated toxins are primarily used as antigens in vaccines to protect against diseases caused by potent bacterial exotoxins, such as tetanus and diphtheria, by inducing long-lasting humoral immunity without causing the illness itself.^[2] The development of toxoid vaccines represents a cornerstone in modern immunology, emerging in the early 20th century as a safer alternative to live or whole-organism vaccines. Tetanus toxoid was first produced in 1924 through formaldehyde treatment of the tetanus toxin produced by Clostridium tetani, which proved crucial for tetanus prophylaxis during World War II for wounded soldiers.^[3] Similarly, diphtheria toxoid, derived from the toxin of Corynebacterium diphtheriae, was developed in 1923 and refined for widespread use by the mid-1920s.^[4] These innovations laid the foundation for combination vaccines, such as diphtheria-tetanus-pertussis (DTP), which have been integral to global immunization programs since the 1940s.^[5] Toxoids are most notably employed in vaccines against tetanus, diphtheria, and, in some formulations, pertussis, where the pertussis component may include toxoid elements alongside other antigens. For instance, the tetanus toxoid vaccine elicits a strong protective antibody response after initial doses, with boosters recommended every 10 years to maintain immunity.^[6] Diphtheria toxoid similarly prevents the severe respiratory and systemic effects of the disease by targeting the toxin's ability to inhibit protein synthesis in host cells.^[7] These vaccines are often adsorbed onto adjuvants like aluminum salts to enhance immunogenicity and reduce the required dose, a technique pioneered in the mid-20th century.^[8] The production of toxoids typically involves culturing the toxin-producing bacteria under controlled conditions, purifying the exotoxin, and then detoxifying it—most commonly with formaldehyde—to render it non-toxic while retaining its antigenic structure. This process ensures the toxoid mimics the native toxin enough to train the immune system effectively but without the risk of pathogenesis.^[2] Advances in genetic engineering have also led to recombinant toxoids, such as detoxified tetanus toxin fragments, offering potential improvements in safety and efficacy for future vaccine designs.^[9]

Definition and Mechanism

Definition

A toxoid is a chemically inactivated form of a bacterial exotoxin that has been rendered nontoxic while preserving its ability to elicit an immune response, serving as the key antigen in toxoid vaccines to protect against toxin-mediated diseases.^[10] These vaccines target the harmful products secreted by bacteria rather than the bacteria themselves, inducing the production of neutralizing antibodies that bind to the toxin and prevent its pathological effects.^[11] In contrast to native bacterial toxins, which are potent virulence factors that cause disease through specific molecular mechanisms such as enzymatic modification of host cell components—for instance, diphtheria toxin catalyzing the ADP-ribosylation of elongation factor 2 to halt protein synthesis—toxoids undergo detoxification to eliminate these harmful activities without compromising their immunogenic properties.^[12] This inactivation ensures that toxoids no longer disrupt cellular processes like signal transduction or membrane integrity, which native toxins exploit to induce symptoms, but instead safely mimic the toxin's structure to stimulate protective immunity.^[13] The predominant type of toxoid is produced through formaldehyde inactivation, a process that chemically modifies the toxin to abolish toxicity while maintaining its overall conformation.^[14] Emerging alternatives include genetic toxoids, created by mutating the toxin's gene to produce a nontoxic variant, though these remain under development and are not yet widely used.^[15] At the immunological level, toxoids function as antigens—molecules capable of provoking an adaptive immune response—by retaining key epitopes, the specific structural regions recognized by B cells and T cells to generate antibodies and memory cells.^[16] This preservation of epitopes is crucial, as it allows the immune system to produce high-affinity antibodies that neutralize the original toxin upon subsequent exposure, without triggering the toxin's disease-causing effects.^[17]

Mechanism of Action

Toxoids function as antigens by mimicking the structure of bacterial exotoxins while being rendered non-toxic, thereby eliciting an immune response without causing harm. Upon administration, toxoid antigens are taken up by antigen-presenting cells, such as dendritic cells, which process and present toxoid-derived peptides on major histocompatibility complex (MHC) class II molecules to CD4+ T-helper cells. This interaction activates T-helper cells, which release cytokines to stimulate B-cell proliferation and differentiation.^[18]^[19] The activated B cells undergo clonal expansion and class switching, primarily producing immunoglobulin G (IgG) antibodies known as neutralizing antitoxins. These antitoxins specifically bind to the corresponding toxin upon subsequent exposure, sterically hindering the toxin's ability to interact with host cell receptors or enzymes, thus preventing cellular damage and disease manifestation. This humoral response is T-cell dependent, ensuring affinity maturation and the generation of high-avidity antibodies for effective neutralization.^[20]^[18]^[19] In the broader context of adaptive immunity, toxoid vaccination promotes the formation of memory B cells and long-lived plasma cells, providing durable protection against toxin-mediated pathology. Unlike live attenuated vaccines, which replicate within the host to amplify antigen presentation and induce both humoral and robust cellular immunity, toxoids depend entirely on the injected antigenic material for stimulation, eliminating any risk of replication or reversion to virulence. This safer profile, however, often results in gradually waning antibody levels over time, necessitating periodic booster doses to maintain protective thresholds.^[21]^[19]^[22] Protective immunity is quantitatively assessed by measuring serum antibody titers, typically through enzyme-linked immunosorbent assay (ELISA) for total antitoxin levels or in vitro toxin neutralization assays to evaluate functional neutralizing capacity, with thresholds such as >0.01 IU/mL for tetanus and >0.1 IU/mL for diphtheria indicating protection. Studies have shown that antitoxin levels decline at variable rates post-vaccination, underscoring the importance of boosters every 10 years to sustain long-term memory responses.^[23]^[24]^[25]^[26]

Historical Development

Early Discoveries

In the late 19th century, the foundational work on bacterial toxins and their neutralization laid the groundwork for toxoid development. In 1890, German bacteriologist Emil von Behring and Japanese scientist Shibasaburo Kitasato demonstrated that serum from animals immunized with diphtheria toxin could protect against the disease, identifying key toxin-antitoxin interactions through experiments on guinea pigs and other animals.^[27]^[28] Their collaborative research, published that year, showed that repeated sublethal doses of toxin induced protective antibodies, marking the first effective passive immunization against diphtheria and extending similar findings to tetanus toxin.^[29]^[30] The urgency for safer immunization methods intensified during World War I (1914–1918), when epidemics of diphtheria and, especially, tetanus ravaged troops due to contaminated wounds in trench warfare, resulting in thousands of cases and highlighting the limitations of live toxins or infectious agents for prophylaxis.^[31] Tetanus incidence was particularly high among soldiers, with antitoxin serum providing some passive protection but failing to offer long-term active immunity, thus driving post-war research toward non-infectious alternatives.^[3] In the 1920s, French veterinarian Gaston Ramon advanced this field by developing toxoids through chemical and thermal inactivation of diphtheria toxin. In 1923, Ramon discovered that treating diphtheria toxin with formalin (formaldehyde solution) at 37–40°C for several weeks eliminated its toxicity while retaining its ability to stimulate antibody production, a process he termed "anatoxin."^[32]^[33] This method was independently developed in the same year by British researcher Alexander T. Glenny.^[34] Ramon and others, including P. Descombey, applied similar methods to tetanus toxin, with Descombey producing the first tetanus toxoid in 1924, enabling safe active immunization.^[35]^[28] Early validation involved immunizing horses to produce high-titer antitoxins and testing the toxoids' efficacy in guinea pigs, where injected animals survived otherwise lethal toxin challenges, confirming preserved antigenicity without harm.^[35]^[28] These experiments demonstrated that toxoids could induce robust, lasting immunity in mammals, paving the way for broader prophylactic use.

Key Milestones in Vaccine Use

The first human use of diphtheria toxoid occurred in 1923, when French veterinarian and immunologist Gaston Ramon demonstrated that treating diphtheria toxin with formalin and heat eliminated its toxicity while preserving its immunogenicity, marking the beginning of active immunization against the disease.^[32] This breakthrough shifted vaccination efforts from passive antitoxin therapy to preventive toxoid administration, enabling safer and more scalable protection.^[2] In the 1930s, tetanus toxoid was introduced for military applications, with widespread adoption during World War II that significantly reduced wound-related infections and tetanus cases among soldiers. By 1936, it became obligatory in the French army, and its mandated use in the U.S. military from 1941 onward contributed to near-elimination of tetanus in combat settings.^[2]^[36] This success highlighted toxoids' role in high-risk environments and paved the way for broader civilian immunization.^[33] The 1940s and 1950s saw the development of the combined diphtheria-tetanus-pertussis (DTP) vaccine, integrating diphtheria and tetanus toxoids with a whole-cell pertussis component for efficient childhood immunization. Pioneered in 1942 by researchers including Pearl Kendrick and Grace Eldering, the formulation was licensed in 1948 and became a cornerstone of routine vaccination programs, dramatically lowering incidence of all three diseases.^[37] From the 1980s onward, the World Health Organization's Expanded Programme on Immunization (EPI), launched in 1974 but gaining momentum post-smallpox eradication in 1980, drove global toxoid campaigns that virtually eliminated diphtheria in regions like the Americas by the 1990s and reduced reported cases by over 90% worldwide between 1980 and 2000 through routine DTP immunization. By 2020, global coverage for the third dose of DTP-containing vaccines reached 85%, averting millions of deaths and establishing toxoids as essential tools in public health.^[38]^[39] A key recent advancement came in the 1990s, when acellular pertussis toxoids replaced whole-cell versions in DTP vaccines (now DTaP) in many countries, including the United States, to improve safety by reducing local and systemic side effects while maintaining efficacy.^[40]

Production Methods

Inactivation Techniques

The primary method for converting bacterial toxins into toxoids is chemical inactivation using formaldehyde (formalin), which detoxifies the protein while retaining its immunogenic epitopes. Purified toxin is typically incubated with 0.4% formaldehyde at a controlled pH of approximately 7.8 and temperature of 37°C for 4 to 6 weeks, promoting the formation of irreversible methylene bridges between lysine and other amino acid residues, thereby disrupting the toxin's enzymatic and toxic activities without completely denaturing its structure.^[41] This process, first optimized in the early 20th century for tetanus and diphtheria toxins, is standardized to minimize reversion to toxicity and ensure vaccine safety.^[42] Alternative inactivation techniques have been explored to address limitations of formaldehyde, such as potential residual toxicity or lengthy processing times, though none have supplanted it as the dominant approach due to formaldehyde's specificity in preserving antigenicity. Heat treatment at elevated temperatures (e.g., 60–80°C) can denature toxins but often compromises immunogenicity more severely, limiting its use to experimental or adjunct roles. Chemical alternatives like glutaraldehyde form stronger cross-links for rapid detoxification but may over-stabilize the protein, reducing epitope exposure and vaccine potency; hydrogen peroxide offers a milder oxidative inactivation with lower risk of chemical residues, yet it is less commonly applied owing to variable efficacy across toxin types, as seen in pertussis toxoid development.^[43] Formaldehyde's prevalence stems from its proven balance of detoxification efficiency and immunological fidelity in licensed vaccines.^[44] Verification of complete inactivation is critical and involves rigorous animal toxicity testing to confirm negligible residual activity. Standard protocols, as outlined by WHO, employ guinea pig or mouse models where bulk toxoid (e.g., at doses equivalent to 500 Lf units for tetanus) is administered subcutaneously or intraperitoneally, with observation for 21 days; no signs of paralysis or lethality must occur, indicating toxicity reduced to undetectable levels (often below 1/10,000th of the native toxin's potency in sensitive assays).^[42] Reversion tests further incubate the toxoid at 37°C for 6 weeks before retesting to ensure stability.^[42] Additionally, genetic engineering produces recombinant toxoids like CRM197, a non-toxic diphtheria toxin mutant with a G52E substitution that abolishes ADP-ribosyltransferase activity, bypassing chemical inactivation altogether while mimicking native immunogenicity.^[45] Recent advances include genetically detoxified tetanus toxoids, such as the 8MTT variant with eight amino acid mutations that reduce toxicity by over 50 million-fold compared to the native toxin.^[7]

Formulation and Standardization

Following inactivation of the toxin to produce the toxoid, the material is purified and prepared for vaccine formulation to ensure stability and immunogenicity. Toxoids are typically adsorbed onto aluminum salts, such as aluminum hydroxide or aluminum phosphate, which serve as adjuvants to enhance the immune response through slow release of the antigen and stimulation of innate immunity.^[46] These adjuvants are added at concentrations not exceeding 1.25 mg per single human dose to avoid excessive reactogenicity while boosting antibody production.^[47] To maintain stability, preservatives like thimerosal (also known as thiomersal) are incorporated into multi-dose vials at low concentrations to prevent microbial contamination, while buffers such as phosphate or histidine are added to keep the pH between 6 and 7, approximating physiological conditions and preventing degradation.^[48]^[49] This formulation supports storage at 2–8°C, where vaccines retain potency for a typical shelf-life of 2–3 years, though some may be lyophilized to extend stability in challenging environments.^[47] Standardization follows World Health Organization (WHO) guidelines to verify potency and purity, with toxoid preparations required to achieve a minimum of 1,000 Lf (Limes flocculation) units per milligram of protein nitrogen in bulk form.^[9] Potency is assessed using in vivo limiting dilution tests in guinea pigs, where serial dilutions of the vaccine are administered and compared to an international reference standard to ensure at least 40 International Units (IU) per human dose for primary immunization, confirming protective efficacy.^[50] These measures ensure batch-to-batch consistency and compliance with regulatory requirements for safe deployment.^[47]

Clinical Applications

Monovalent Toxoid Vaccines

Monovalent toxoid vaccines consist of purified, inactivated toxins from a single bacterial pathogen, administered to elicit immunity against specific toxin-mediated diseases without incorporating other antigens.^[51] These vaccines primarily target illnesses caused by potent exotoxins, such as tetanus, which produces lockjaw (trismus) and generalized muscle spasms that can progress to respiratory failure, and diphtheria, where the toxin forms pseudomembranes in the throat leading to airway obstruction and potential suffocation.^[52]^[53] Tetanus infection arises from Clostridium tetani spores entering wounds, while diphtheria stems from Corynebacterium diphtheriae colonizing the upper respiratory tract, both resulting in high mortality if untreated due to toxin effects on nerves and tissues.^[54]^[55] Standard dosing regimens for monovalent toxoid vaccines follow a primary immunization series of three doses given intramuscularly at approximately 2, 4, and 6 months of age to establish initial immunity in infants.^[56] This schedule aligns with early childhood protection needs, with subsequent boosters recommended every 10 years throughout adulthood to maintain antibody levels against tetanus and diphtheria toxins, preventing waning immunity that could allow disease resurgence.^[57] For maternal and neonatal protection, particularly in tetanus-endemic areas, a regimen of at least two doses of monovalent tetanus toxoid during pregnancy—spaced 4 weeks apart, with the first as early as possible—ensures passive antibody transfer to newborns.^[58] Overall, lifelong protection requires six lifetime doses, including the primary series and boosters, to sustain antitoxin levels above protective thresholds.^[59] Administration of monovalent toxoid vaccines occurs via intramuscular injection to optimize absorption and immune response, with the site varying by age: the anterolateral thigh for infants and young children to accommodate smaller muscle mass, and the deltoid muscle for adults.^[59] Pediatric formulations typically contain higher antigen doses, such as at least 30 international units (IU) of diphtheria toxoid per dose, to account for immature immune systems, whereas adult versions use reduced amounts (2–5 IU) to minimize reactogenicity while still conferring protection.^[60] Deep injection technique is essential, using a 22–25 gauge needle of appropriate length (e.g., 25 mm for children, 38 mm for adults) to reach the muscle without subcutaneous deposition, which could reduce efficacy.^[61] In low-resource settings, monovalent toxoid vaccines play a pivotal role in global health through the World Health Organization's Expanded Programme on Immunization (EPI), launched in 1974 to deliver routine vaccinations and achieve universal access to essential immunogens like tetanus toxoid for maternal immunization.^[62] The EPI facilitates integration into national health systems, targeting high-burden areas to eliminate maternal and neonatal tetanus, with monovalent formulations enabling focused campaigns where combination vaccines are unavailable.^[63] This approach has supported tetanus elimination in 49 countries (as of December 2024) by providing cost-effective, heat-stable options suitable for outreach in remote or underserved communities.^[64]^[58]

Use in Combination Vaccines

Toxoids are frequently integrated into combination vaccines to provide broad-spectrum protection against multiple infectious diseases in a single administration, enhancing efficiency in immunization strategies. Building on monovalent toxoid vaccines, these combinations incorporate diphtheria toxoid, tetanus toxoid, and acellular pertussis toxoid as core elements.^[65] A prominent example is the DTaP vaccine, which targets diphtheria, tetanus, and pertussis in infants and young children through these toxoid components.^[66] For adolescents and adults, the Tdap vaccine delivers a reduced dose of the same toxoids to maintain immunity while minimizing reactogenicity.^[67] Hexavalent vaccines, such as Vaxelis, extend this approach by combining the DTaP toxoids with inactivated poliovirus, hepatitis B, and Haemophilus influenzae type b antigens, offering comprehensive early childhood protection.^[68] The primary benefits of incorporating toxoids into combination vaccines include a decreased number of required injections, which streamlines vaccination visits and reduces logistical burdens on healthcare systems.^[69] This approach also improves vaccination compliance by simplifying schedules for parents and providers, leading to higher overall coverage rates.^[70] Furthermore, these formulations support effective immunity across antigens without clinically significant interference, as the immune system adeptly handles multiple components simultaneously.^[71] Despite these advantages, challenges arise from potential antigenic competition in multi-component vaccines, where the presence of multiple antigens may diminish responses to individual toxoids, often necessitating formulation adjustments like higher antigen doses or inclusion of adjuvants to optimize immunogenicity.^[72]^[73] Toxoid-containing combination vaccines are seamlessly integrated into national immunization programs worldwide, with the DTaP series typically following a 5-dose schedule administered at 2, 4, and 6 months, 15–18 months, and 4–6 years of age to ensure sustained protection through early childhood.^[65] Similar schedules apply to hexavalent vaccines in regions where they are recommended, aligning with routine pediatric visits to maximize adherence.^[74]

Examples of Common Toxoids

Diphtheria Toxoid

The diphtheria toxoid is an inactivated form of the exotoxin produced by the bacterium Corynebacterium diphtheriae, the causative agent of diphtheria. This exotoxin, known as diphtheria toxin, exerts its pathogenic effects by entering host cells and catalyzing the NAD+-dependent ADP-ribosylation of elongation factor 2 (EF-2), a critical component of the ribosomal translocation step in protein synthesis. This modification inactivates EF-2, halting polypeptide chain elongation and ultimately leading to cell death.^[75]^[76] Diphtheria toxoid vaccines exist in both fluid (non-adsorbed) and adsorbed forms, with the adsorbed variant—typically bound to aluminum salts like aluminum phosphate or hydroxide—predominating in modern formulations to prolong antigen presentation and boost immune response. Vaccine potency is standardized using Lf (Limes flocculation) units, a measure derived from the flocculation reaction between toxoid and specific antitoxin, where one Lf unit corresponds to the amount of toxoid that flocculates with one unit of antitoxin. Pediatric doses commonly contain 10–30 Lf units, while adult formulations use lower amounts (2–5 Lf units) to minimize reactogenicity without sacrificing efficacy.^[77]^[8] The toxoid specifically targets the toxin's systemic damage, preventing hallmark manifestations of diphtheria such as the formation of adherent pseudomembranes in the pharynx or tonsils, which can obstruct airways, and toxin-mediated complications like myocarditis, which affects cardiac conduction and function. Importantly, immunization induces neutralizing antibodies against the toxin but does not eradicate bacterial colonization or prevent asymptomatic carriage of C. diphtheriae, necessitating antibiotics for infection control.^[78]^[79] A distinctive feature of diphtheria toxoid is its role as a carrier protein in conjugate vaccines for infants, particularly the non-toxic mutant CRM197, which shares antigenic similarity with the native toxoid and enables T-cell help for polysaccharide antigens in vaccines against pathogens like Haemophilus influenzae type b or pneumococcus. This cross-reactivity can enhance or interfere with anti-toxoid responses during co-administration, potentially boosting diphtheria immunity through carrier priming but requiring careful scheduling to avoid hyporesponsiveness in subsequent doses.^[80]^[81]

Tetanus Toxoid

The tetanus toxoid is an inactivated form of tetanospasmin, the primary neurotoxin produced by the bacterium Clostridium tetani. This toxin, released during spore germination in anaerobic environments such as deep wounds, binds to nerve terminals and is transported retrogradely to the central nervous system, where it cleaves synaptobrevin, a protein essential for vesicle fusion, thereby blocking the release of inhibitory neurotransmitters like glycine and GABA. This inhibition leads to unopposed muscle contraction and characteristic spasms, ranging from localized rigidity to generalized lockjaw and fatal respiratory failure. The toxoid is prepared by treating purified tetanospasmin with formalin to detoxify it while preserving its immunogenicity, allowing it to stimulate antibody production without causing disease.^[82]^[83]^[84] Development of the tetanus toxoid began in the early 20th century, with Gaston Ramon at the Pasteur Institute successfully inactivating the toxin in 1923 using formalin, leading to the first human trials in 1924. Its efficacy was demonstrated during World War II, where widespread administration to soldiers reduced tetanus incidence dramatically among wounded troops, prompting its integration into routine immunization programs in the late 1940s. The toxoid plays a critical role in wound prophylaxis, particularly for tetanus-prone injuries like punctures or contaminated lacerations, where immediate administration of a booster dose is recommended alongside wound cleaning to provide rapid passive and active immunity, even in those with incomplete vaccination history.^[85]^[3]^[86] Tetanus toxoid is highly immunogenic, eliciting robust and long-lasting humoral immunity with a primary series of three doses typically conferring protection for at least 10 years, after which boosters maintain antibody levels. It is often formulated as a standalone monovalent vaccine, adsorbed onto aluminum salts for enhanced potency, and used specifically for adult boosters or post-exposure prophylaxis in resource-limited settings where combination vaccines are unavailable. This standalone preparation requires fewer doses overall compared to primary immunization schedules due to its potent antigenic properties and the toxin's high toxicity, which translates to strong immune memory.^[87]^[88] In populations with high vaccination coverage, tetanus has been nearly eliminated, with cases in the United States dropping to fewer than 30 annually since the 1940s, primarily among unvaccinated or under-vaccinated individuals. Globally, vaccination has reduced neonatal tetanus deaths by 97% since 1988, from over 800,000 to about 25,000 in 2018, though risks persist in low-income regions where unhygienic umbilical cord practices during home births allow C. tetani spore contamination, leading to severe outcomes in unprotected newborns.^[89]^[3]^[90]

Pertussis Toxoid

Pertussis toxoid is derived from the toxins produced by Bordetella pertussis, the bacterium responsible for whooping cough, with pertussis toxin (PT) and filamentous hemagglutinin (FHA) serving as primary components that elicit protective immunity. PT, an AB5-type exotoxin, is the main virulence factor causing systemic effects such as lymphocytosis and the characteristic coughing paroxysms by disrupting host cell signaling and promoting bacterial adhesion to respiratory epithelium.^[91]^[92]^[93] FHA, a surface protein, facilitates bacterial attachment to ciliated epithelial cells, contributing to the prolonged cough and mucosal damage observed in pertussis infections.^[92]^[94] The development of pertussis toxoids marked a significant evolution from whole-cell pertussis (wP) vaccines, which used inactivated whole bacteria, to acellular pertussis (aP) formulations in the 1990s, driven by the need to minimize reactogenicity such as high fever and local swelling associated with wP vaccines. This shift occurred following international clinical trials in the 1990s that demonstrated aP vaccines' superior safety profile while maintaining efficacy against severe disease, leading to their widespread adoption in routine immunization schedules, including the replacement of wP in the combined diphtheria-tetanus-pertussis (DTP) vaccine introduced historically in the 1940s.^[40]^[95]^[96] In aP vaccines, PT is inactivated to eliminate toxicity while preserving immunogenicity, typically through chemical treatments like formaldehyde or glutaraldehyde, which cross-link proteins to abolish enzymatic activity, or via genetic mutations in the toxin's S1 subunit to create non-toxic variants. These detoxified PT antigens are often combined with FHA and adjuvants such as aluminum salts to enhance immune responses, resulting in formulations that include 5–30 µg of PT and 5–25 µg of FHA per dose, depending on the vaccine brand.^[97]^[98]^[99] Genetically inactivated PT has shown comparable immunogenicity to chemically treated versions in preclinical models, offering potential for more stable and consistent vaccine production.^[100]^[101] Pertussis toxoid vaccines have substantially reduced severe cases and hospitalization rates among infants, with effectiveness exceeding 80% against laboratory-confirmed pertussis in the first year post-vaccination, though protection wanes over time, dropping to around 70% after 4–5 years and necessitating adolescent booster doses like Tdap to sustain herd immunity and prevent outbreaks.^[91]^[102]^[103]

Safety and Efficacy

Adverse Effects

Toxoid vaccines are generally well-tolerated, with most adverse effects being mild and transient. Local reactions at the injection site, such as pain, redness, and swelling, occur in approximately 10-20% of recipients and typically resolve within 1-2 days without intervention.^[8] These reactions are more frequent with higher doses of toxoid but do not usually interfere with daily activities.^[104] Systemic effects, including low-grade fever, fatigue, headache, and malaise, affect 5-15% of individuals following toxoid vaccination and generally last 1-3 days.^[104] Such symptoms can be managed with rest, hydration, and over-the-counter analgesics like acetaminophen. Severe allergic reactions, such as anaphylaxis, are exceedingly rare, occurring in about 1 in 1 million doses.^[105] Rare severe events have been reported, including potential associations with Guillain-Barré syndrome following administration of certain early toxoid formulations, though causality has not been consistently confirmed in modern studies.^[106] For instance, acellular pertussis toxoid in combination vaccines shows no established link to such neurologic events.^[104] Individuals with a history of severe allergic reactions to vaccine components require precautions, such as pre-vaccination assessment and availability of epinephrine.^[107] Toxoid vaccines are considered safe for immunocompromised persons, but close monitoring for response and any unusual symptoms is recommended due to potential variations in immune function.^[107]

Clinical Effectiveness

Toxoid vaccines demonstrate high clinical effectiveness in preventing targeted diseases following a complete primary series. For diphtheria, vaccine effectiveness reaches 97% against clinical cases with three or more doses of diphtheria toxoid-containing vaccines. Similarly, tetanus toxoid provides over 95% protection for at least 10 years post-vaccination, with long-term studies indicating that 95% of recipients maintain immunity for 30 years or more without boosters. A 2016 US cross-sectional analysis confirmed that 97% of the population had protective tetanus antibody levels, with models predicting 95% seroprotection persisting for at least 30 years in vaccinated individuals.^[108] Acellular pertussis toxoids achieve 80-90% efficacy against disease in fully vaccinated children, though protection wanes significantly after 5-10 years, dropping to approximately 71% by five years post-fifth dose. Key historical and cohort studies underscore these efficacy profiles. Long-term data from U.S. military immunization programs in the 1940s, which introduced routine tetanus toxoid, showed near-complete protection, with tetanus cases declining by over 99% through the 2000s due to widespread vaccination. For pertussis, a 2012 New England Journal of Medicine study on California outbreaks highlighted initial high efficacy followed by waning, emphasizing the need for boosters. Herd immunity thresholds for diphtheria require approximately 85% coverage with three doses of DTP vaccine, while for pertussis it is around 92-94%, to interrupt transmission effectively. Tetanus vaccination provides individual protection but does not confer herd immunity as the disease is not contagious.^[109]^[110] Serological correlates of protection are well-established for toxoids. For tetanus, antibody levels of ≥0.1 IU/mL are considered fully protective against disease, correlating with clinical outcomes in vaccinated individuals. Diphtheria protection similarly aligns with ≥0.1 IU/mL antitoxin levels, while pertussis relies on IgG responses, though exact thresholds vary due to waning immunity. Globally, toxoid vaccination has dramatically reduced disease incidence. Diphtheria cases declined by over 90% in the post-vaccination era, from tens of thousands annually in the early 1940s to fewer than 100 in the U.S. by the 1980s, a trend mirrored worldwide with high coverage.

References

[1]
Appendix 1: Glossary | Vaccines & Immunizations - CDC
Feb 10, 2023 · Toxoid. A modified bacterial toxin that has been made nontoxic, but retains the ability to stimulate the formation of antibodies to the toxin.
[2]
Vaccines: Past, Present, and Future - NCBI - NIH
Toxoids are toxins that have been treated by physical or chemical means until they no longer produce clinical disease, but retain the capacity to induce ...
[3]
Vaccines Through Centuries: Major Cornerstones of Global Health
At the beginning of World War I, the tetanus toxoid was introduced, followed in 1915 by the pertussis vaccine. In 1974, The Expanded Program of Immunization was ...
[4]
Diphtheria and Tetanus Toxoids - Adverse Events Associated ... - NCBI
Diphtheria toxoid adsorbed with aluminum hydroxide or phosphate was shown to be more immunogenic and to produce fewer local reactions than fluid toxoid. The ...
[5]
History of vaccination - PMC - NIH
Yellow fever (1935), Influenza (1936), Tetanus toxoid (1926) ; Rickettsia (1938) ; 20th Century, second half ; Polio (oral) (1963), Polio (injected) (1955) ...Table 1 · Reassortment · Genetic Engineering
[6]
Tetanus Toxoid - StatPearls - NCBI Bookshelf - NIH
Tetanus toxoid is a vaccine used to manage and treat tetanus, protecting against the bacteria Clostridium tetani. It is also used for wound care.
[7]
Recent Developments in Vaccine Design - PubMed Central - NIH
Toxoid vaccines have been used since the 1920s and are known to elicit a strong and protective humoral immune response after initial vaccination [33,34], but ...
[8]
Genetically detoxified tetanus toxin as a vaccine and conjugate ...
Tetanus toxoid (TTxd), developed over 100 years ago, is a clinically effective, legacy vaccine against tetanus. Due to the extreme potency of native tetanus ...
[9]
What is a Toxoid Vaccine? - News-Medical
Toxoid vaccines use toxoids (as antigens) to induce an immune response in protecting against diseases caused by toxins secreted by specific bacteria.Examples Of Bacterial... · Tetanus · Dpt Vaccine
[10]
Vaccine Types - HHS.gov
Dec 22, 2022 · Toxoid vaccines use a toxin (harmful product) made by the germ that causes a disease. They create immunity to the parts of the germ that cause a ...Hepatitis A · Rotavirus · Vaccines by Disease · Chickenpox (Varicella)
[11]
Overview of Bacterial Protein Toxins from Pathogenic Bacteria - MDPI
Toxins active at the cell membrane use either a transduction, pore formation, or enzymatic hydrolysis mechanism. Intracellularly active toxins exploit short or ...4. Bacterial Protein Toxins... · 5. Bacterial Protein Toxins... · 5.1. Toxins Inducing Cell...
[12]
Some Examples of Bacterial Toxins as Tools - PMC - NIH
Apr 23, 2024 · Overall, one can state that engineered immunotoxins are on the way to becoming effective therapeutic agents. 3.2. The Deamidating Toxins CNF, ...
[13]
Inactivated Viral Vaccines - PMC - NIH
Formaldehyde is the most widely used inactivating agent for vaccine purposes and many pathogens have been subjected to the irreversible modifications ...
[14]
Toxin inactivation and antigen stabilization: two different uses of ...
With the development of vaccines that are detoxified by genetic manipulation, formaldehyde has a new role as a stabilizer of such genetically detoxified ...
[15]
T-cell epitope vaccine design by immunoinformatics - PMC - NIH
Such toxoid vaccines are produced by treating the toxins with formalin, thus inactivating them, and still retaining their structure for further recognition by ...
[16]
Epitope Profiling of Diphtheria Toxoid Provides Enhanced ... - NIH
May 13, 2022 · An innovative, quantitative epitope profiling method which provides an extended immunochemical analysis for diphtheria toxoid (DTxd) to be used for consistency ...
[17]
A guide to vaccinology: from basic principles to new developments
Dec 22, 2020 · For example, antitoxin antibodies, which are induced by the tetanus toxoid vaccine, confer protection directly by neutralizing the activity of ...
[18]
Fundamentals of Vaccine Immunology - PMC - NIH
... memory is weaker than with T-helper cell activation. In contrast, activation of B–cells with T-helper cell activation results in a much better immune ...
[19]
Toxoid - an overview | ScienceDirect Topics
Toxoids are modified bacterial exotoxins, often inactivated by heat or formaldehyde, used in vaccines to stimulate an immune response.
[20]
Chapter 1: Principles of Vaccination | Pink Book - CDC
Mar 22, 2024 · Toxoid vaccines are made using inactivated toxins produced by bacteria. These protein-based toxins are inactivated using heat, chemicals, or ...At A Glance · Immunology And... · Classification Of Vaccines<|control11|><|separator|>
[21]
Understanding Six Types of Vaccine Technologies - Pfizer
Toxoid vaccines use inactivated toxins to target the toxic activity created by the bacteria, rather than targeting the bacteria itself. “The goal of toxoid ...Live-Attenuated Vaccines · Subunit Vaccines · Toxoid Vaccines
[22]
Development of an ELISA for measuring the activity of tetanus toxoid ...
The ELISA was found to measure antibody levels as low as 5.8 x 10(-5) IU/ml. Furthermore, a comparison of the results from ELISA and TNT involving 132 different ...
[23]
Immunity to Diphtheria Toxoid: Waning Rate & Duration
Jul 21, 2022 · In this study, we quantified the peak immunity and waning rate of anti-diphtheria antitoxoid antibodies after different numbers of DTP doses. We ...
[24]
Prevention of Pertussis, Tetanus, Diphtheria Vaccines US: ACIP
Apr 27, 2018 · After receiving 3 doses of tetanus toxoid–containing vaccine, virtually all infants and adults develop protective tetanus antitoxin titers >0.1 ...
[25]
Diphtheria Treatments and Prevention
In 1890, an effective treatment for diphtheria – antitoxin – was discovered by Shibasaburo Kitasato and Emil von Behring in Germany.
[26]
Remembering Emil von Behring: from Tetanus Treatment to ...
Feb 28, 2017 · He was the first to be honored by the Nobel Prize for Medicine in 1901 for the successful therapy of diphtheria and tetanus, which he had ...
[27]
A centennial review; the 1890 tetanus antitoxin paper of von Behring ...
The significance of the 1890 tetanus antitoxin paper by von Behring and Kitasato in the development of a new discipline, immunology, is reviewed.
[28]
Shibasaburo Kitasato (1853-1931): Pioneer of Japanese Medicine ...
Aug 31, 2024 · Kitasato's collaborative work with Emil von Behring on diphtheria and tetanus immunity in animals, published in 1890, was another landmark ...
[29]
Early U.S. Military Immunization Against Tetanus and Diphtheria - NIH
Aug 20, 2025 · Prior to the Second World War, toxoid immunizations for both tetanus and diphtheria had been developed but were not widely used in adults.
[30]
Chapter 21: Tetanus | Pink Book - CDC
Apr 25, 2024 · Tetanus is an acute, often fatal, disease caused by an exotoxin produced by the bacterium Clostridium tetani.
[31]
Diphtheria antitoxin treatment: from pioneer to neglected - PMC
In 1923 began the era of human toxoid vaccination, after Gaston Ramon demonstrated that formalin combined with heat eliminated the toxicity of the diphtheria ...
[32]
Gaston Ramon's Big Four - PMC - PubMed Central
Jan 9, 2024 · “Gaston Ramon was born here on September 30, 1886. Inventor of diphtheria and tetanus toxoids. Honorary Director of the Pasteur Institute” ( ...
[33]
Gaston Ramon's Big Four - MDPI
Jan 9, 2024 · Until 1922, the titration of the antitoxic power of sera was carried out by in vivo neutralization tests in guinea pigs and sometimes in mice, ...
[34]
Pertussis and Rubella Vaccines: A Brief Chronology - NCBI - NIH
1930s-1940s In 1942, she and colleagues combine her improved killed vaccine with diphtheria and tetanus toxoids to produce the diphtheria-tetanus-pertussis ( ...Missing: military | Show results with:military
[35]
Recommendations to assure the quality, safety and efficacy of ...
... 1980–2000, the reported number of diphtheria cases was reduced by more than 90%. However, diphtheria is still a significant health concern in countries with ...Missing: eradication | Show results with:eradication
[36]
WHO Immunization Data portal - Global
Global Vaccination coverage trendline ; BCG. 88% · 1980 · 15% ; DTP-containing vaccine, 1st dose. 89% · 1980 · 30% ; DTP-containing vaccine, 3rd dose. 85% · 1980 · 20%.Measles vaccination coverage · Diphtheria reported cases and... · All Data · AlbaniaMissing: eradication campaigns
[37]
Licensed pertussis vaccines in the United States - NIH
In 1948, the pertussis vaccine was combined with diphtheria and tetanus toxoids and became a diphtheria whole cell pertussis and tetanus toxoid (DTP) vaccine.Missing: 1940s 1950s
[38]
Application to Tetanus Toxoid Ligand Identification - PMC - NIH
tetani is inactivated by cross-linking for four to six weeks at 37 °C using 40% formaldehyde. Bacteria can secrete different proteins into the medium during ...<|control11|><|separator|>
[39]
None
Summary of each segment:
[40]
Pertussis Toxin: A Key Component in Pertussis Vaccines? - PMC
Sep 21, 2019 · Many chemical detoxification methods have been used, including formaldehyde, glutaraldehyde, hydrogen peroxide, and tetranitromethane [76,81].
[41]
Vaccine Technologies and Platforms for Infectious Diseases
Toxoid vaccines often induce local injection site reactions that resolves 48–72 h after immunization.
[42]
Structural and immunological characterization of E. coli derived ...
Sep 25, 2018 · CRM197 protein is a nontoxic variant of diphtheria toxin (DT, molecular weight: ~58 kDa) with a single mutation (Glycine to Glutamate ...
[43]
Optimizing the utilization of aluminum adjuvants in vaccines - Nature
Oct 10, 2018 · The immune enhancement effect of precipitation of diphtheria toxoid with insoluble aluminum salts was first reported by Glenny et al. in 1926.
[44]
None
Summary of each segment:
[45]
Thimerosal and Vaccines - CDC
Thimerosal is added to vials of vaccine that contain more than one dose (multi-dose vials) to prevent growth of germs, like bacteria and fungi.Missing: toxoid buffers
[46]
1.6: Vaccine Components - Medicine LibreTexts
Feb 2, 2023 · A buffer solution resists changes in pH when small quantities of an acid or an alkali are added to it. Buffers keep the vaccine at a similar pH ...<|separator|>
[47]
[PDF] WHO Amended Requirements for DTP Vaccines - NIH
The Third International Standard of Diphtheria Toxoid Adsorbed was established in 1999 (8) for determining the potency of vaccines containing diphtheria toxoid.Missing: guidelines formulation
[48]
[PDF] Annex 4 - World Health Organization (WHO)
safety testing, using both the specific toxicity test and the innocuity test, should be performed on the expiry date of the product. Additional tests that may ...
[49]
About Tetanus - CDC
May 30, 2025 · The first sign is most commonly spasms of the jaw muscles, or "lockjaw." Other symptoms can include: Trouble swallowing; Sudden, involuntary ...
[50]
Lessons learned from recent diphtheria cases:
May 11, 2016 · In severe cases, the toxin-producing bacteria Corynebacterium diphtheriae form layers called pseudomembranes. These layers block the airways, ...
[51]
Clinical Features of Tetanus - CDC
Jun 10, 2025 · Trismus, or lockjaw painful muscle contractions ... Tetanus is an uncommon but serious infection caused by bacteria found in the environment.
[52]
[PDF] Operational protocol for clinical management of Diphtheria
Dec 10, 2017 · Signs of respiratory distress (such as fast respiratory rate, severe lower chest wall indrawing and restlessness) are signs of requiring airway ...
[53]
Tetanus | The Australian Immunisation Handbook
Tetanus-toxoid vaccine is recommended in a 5-dose schedule at 2, 4, 6 and 18 months, and 4 years of age. Infants and children receive tetanus toxoid in ...
[54]
Tetanus Vaccination - CDC
Jun 10, 2025 · Adults are recommended to get a tetanus boosters dose every 10 years. Tetanus vaccines are the best way to protect against tetanus and are very ...Missing: monovalent | Show results with:monovalent
[55]
Maternal and Neonatal Tetanus Elimination
Routine immunization with TTCV is reported as Td2+ (two doses or more of tetanus - diphtheria toxoid vaccine)**; countries report achieved coverage annually to ...
[56]
[PDF] Recommendations* for Interrupted or Delayed Routine Immunization
Tetanus - To ensure lifelong protection against tetanus in all people should receive 6 doses (3 primary plus 3 booster doses) of tetanus toxoid-containing ...
[57]
[PDF] information sheet - diphtheria, pertussis, tetanus - The Vaccines
Usually it is available as a preparation adsorbed with aluminium hydroxide or phosphate and combined with other toxoids or vaccine antigens.Missing: formaldehyde | Show results with:formaldehyde
[58]
[PDF] diphtheria and tetanus vaccine (adsorbed
METHOD OF INOCULATION: The vaccine should be injected intramuscularly. The preferred site for injection is deltoid muscle of the upper arm.
[59]
50th anniversary of the Expanded Programme on Immunization (EPI)
Jan 1, 2024 · Building on the momentum of the smallpox eradication effort, EPI was initiated with the goal of providing universal access to life-saving ...
[60]
Essential Programme on Immunization
Building on the momentum of the smallpox eradication effort, the Expanded Programme on Immunization (EPI) was launched in 1974 to ensure that all children ...Missing: 1980s | Show results with:1980s
[61]
Diphtheria Vaccine Recommendations - CDC
May 12, 2025 · CDC recommends routine DTaP vaccination for all infants and children younger than 7 years old. Administer a 5-dose DTaP series, 1 dose at each ...
[62]
[PDF] DTaP (Diphtheria, Tetanus, Pertussis) Vaccine - Immunize.org
children, adolescents, and adults. It is recommended that children receive 5 doses of. DTaP, usually at the following ages: · 2 months. · 4 months. · 6 months.
[63]
Tdap (Tetanus, Diphtheria, Pertussis) Vaccine VIS - CDC
Tdap vaccine can prevent tetanus, diphtheria, and pertussis. Diphtheria and pertussis spread from person to person. Tetanus enters the body through cuts or ...
[64]
[PDF] You Call the Shots: Vaxelis (DTaP-IPV-Hib-HepB) Fact Sheet - CDC
Vaxelis is a hexavalent combination vaccine approved to prevent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B.
[65]
Combination Vaccines for Childhood Immunization - CDC
Combination vaccines merge into a single product antigens that prevent different diseases or that protect against multiple strains of infectious agents causing ...
[66]
[PDF] General Best Practice Guidelines for Immunization
Potential advantages of combination vaccines include 1) improved vaccine coverage rates (41), 2) timely vaccination coverage for children who are behind the ...
[67]
Appendix B: Immunization Management Issues - CDC
Administration of single-antigen or combination vaccine simultaneously with other childhood vaccines produces no clinically significant interference in antibody ...
[68]
[PDF] Combination Vaccines for Childhood Immunization - CDC
Thus, they reduce the number of injections required to prevent some dis- eases. Combination vaccines available for many years include diphtheria and tetanus.
[69]
[PDF] Safety and Mechanism of Action of Licensed Vaccine Adjuvants
Additionally, adju- vants allow for the formulation of complex combination vaccines thereby overcoming antigenic competition. Furthermore, adjuvants are ...
[70]
[PDF] Vaxelis, INN-diphtheria, tetanus, pertussis (acellular, component ...
Vaxelis (DTaP-HB-IPV-Hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, ...
[71]
Corynebacterium Diphtheriae - Medical Microbiology - NCBI Bookshelf
Fragment A catalyzes the NAD+-dependent ADP-ribosylation of elongation factor 2, thereby inhibiting protein synthesis in eukaryotic cells.
[72]
Corynebacterium Diphtheriae - StatPearls - NCBI Bookshelf - NIH
The catalytic domain catalyzes the NAD+ dependent ribosylation of elongation factor 2 and hence inhibits protein synthesis.
[73]
Diphtheria, Tetanus, and Pertussis: Recommendations for Vaccine ...
Each 0.5-mL dose is formulated to contain 2-10 Lf units of tetanus toxoid and less than or equal to 2 Lf units of diphtheria toxoid. Pertussis Vaccine Adsorbed ...
[74]
Clinical Features of Diphtheria - CDC
May 12, 2025 · Respiratory diphtheria can lead to severe complications including myocarditis, neuropathy, airway obstruction, and death. Diphtheria has ...
[75]
Chapter 1: Diphtheria | Manual for the Surveillance of Vaccine ...
Jan 8, 2025 · Although vaccination is highly protective against severe effects of diphtheria toxin, it does not prevent the infection with or carriage of C.
[76]
Protein carriers of conjugate vaccines - PubMed Central - NIH
To date, 5 carrier proteins have been used in licensed conjugate vaccines: a genetically modified cross-reacting material (CRM) of diphtheria toxin, tetanus ...
[77]
Carrier priming to improve pneumococcal disease control and ...
Sep 27, 2016 · This is attributed to the similarity of the diphtheria toxoid antigen to the carrier protein used to make PCV, (known as cross reactive material ...
[78]
Tetanus (Clostridium tetani Infection) - StatPearls - NCBI Bookshelf
Feb 26, 2024 · Tetanus toxin inhibits neurotransmitter release in the brain stem and spinal cord. Wound contamination is the usual entry mode, but in rare ...
[79]
Tetanus: Pathophysiology, Treatment, and the Possibility of Using ...
Jan 8, 2013 · By a mechanism similar to that of botulinum toxin, tetanus toxin is taken up into nerve terminals of lower motor neurons, the nerve cells that ...<|separator|>
[80]
Tetanus Toxoid - an overview | ScienceDirect Topics
It is created by inactivating the toxin with formaldehyde, rendering it immunogenic but non-toxic.
[81]
Nature Milestones in Vaccines
Sep 28, 2020 · By 1938 tetanus toxoid was adsorbed to aluminium adjuvant to make an effective vaccine that was widely used during World War II.<|separator|>
[82]
Tetanus Prophylaxis - StatPearls - NCBI Bookshelf - NIH
Jan 23, 2023 · Prophylaxis should be administered as soon as possible following a wound or traumatic injury and even upon delayed presentation due to the long ...Introduction · Epidemiology · History and Physical · Treatment / Management
[83]
Decennial Administration of a Reduced Antigen Content Diphtheria ...
Booster vaccination against tetanus and diphtheria at 10-year intervals is commonly recommended. Reduced antigen content diphtheria and tetanus toxoids and ...Missing: formulations | Show results with:formulations
[84]
Types of Tetanus Vaccines - CDC
Jun 10, 2025 · Vaccine providers give this vaccine to people 7 years or older. As a booster every 10 years (Tdap is another option for these boosters); As ...
[85]
Tetanus - World Health Organization (WHO)
Jul 12, 2024 · Tetanus is an acute infectious disease caused by spores of the bacterium Clostridium tetani. The spores are found everywhere in the environment.
[86]
Chapter 16: Tetanus | Manual for the Surveillance of Vaccine ... - CDC
Oct 22, 2024 · The effectiveness of tetanus toxoid-containing vaccines is very high, although not 100%4. Vaccination status was known for 67 (25%) tetanus ...Missing: epidemics | Show results with:epidemics
[87]
Chapter 16: Pertussis | Pink Book - CDC
Apr 12, 2024 · Before the availability of pertussis vaccine in the 1940s, more than 200,000 cases of pertussis were reported annually. Since widespread use of ...
[88]
Acellular Pertussis Vaccine Components: Today and Tomorrow - PMC
Pertussis toxin is a key virulence factor that is specific for B. pertussis and responsible for most systemic symptoms associated with pertussis disease [21,22] ...
[89]
Pertussis Toxin: A Key Component in Pertussis Vaccines? - MDPI
Pertussis and its toxins have been investigated by scientists for over a century, yet we still do not have a clear understanding of how pertussis toxin (PT) ...
[90]
A novel vaccine formulation candidate based on ... - Frontiers
Apr 26, 2023 · The currently approved aP vaccine comprises 1 to 5 purified antigens, mainly pertussis toxin (PT) and filamentous hemagglutinin (FHA). The ...
[91]
Pertussis Vaccine Trials in the 1990s - PubMed
Apr 1, 2014 · During the 1990s, collaborative international clinical trials were conducted to evaluate the safety, immunogenicity, and/or efficacy of different acellular ...
[92]
Pertussis: a tale of two vaccines - Nature
Sep 28, 2020 · This acellular pertussis vaccine (aP) was shown to be effective, albeit less so than the whole-cell vaccine, and in 1981 was approved for use ...
[93]
Genetically detoxified pertussis toxin displays near identical ... - Nature
Aug 5, 2020 · To eliminate the deleterious toxic effects, the toxin is inactivated by treatment with chemical agents, such as glutaraldehyde or formaldehyde.
[94]
Properties of pertussis toxin mutant PT-9K/129G after formaldehyde ...
Formaldehyde treatment is a method routinely used to detoxify diphtheria, tetanus, and pertussis toxins as well as other molecules suitable for vaccine ...Missing: toxoid techniques
[95]
Effect of different detoxification procedures on the residual pertussis ...
Apr 19, 2016 · The current detoxification processes include chemical treatments of the toxin with formaldehyde and/or glutaraldehyde, hydrogen peroxide and ...
[96]
Mutants of Pertussis Toxin Suitable for Vaccine Development | Science
Immunization with chemically detoxified pertussis toxin can prevent severe whooping cough with an efficacy similar to that of the cellular pertussis vaccine ...
[97]
Characterization of genetically inactivated pertussis toxin mutants
The introduction of two amino acid substitutions within the enzymatically active subunit Si of pertussis toxin. (PT) abolishes its ADP-ribosyltransferase ...
[98]
What Is Wrong with Pertussis Vaccine Immunity? The Problem ... - NIH
Acellular pertussis vaccines provide protection during the first years of life, but their effectiveness wanes a few years post-boosters.
[99]
Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in ...
Sep 13, 2012 · After the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.
[100]
Diphtheria, Tetanus, and Pertussis Vaccine Safety - CDC
Jan 31, 2025 · It is approved for use in children aged 6 weeks through 4 years of age to protect against diphtheria, tetanus, pertussis, Hib, hepatitis B, and ...Missing: monovalent | Show results with:monovalent
[101]
International Consensus (ICON): allergic reactions to vaccines - PMC
Sep 16, 2016 · The most concerning of these, anaphylaxis, has been estimated to occur at a rate of approximately one per 100,000 to one per 1,000,000 doses ...
[102]
The risk of Guillain-Barré syndrome after tetanus-toxoid-containing ...
This study examined whether there is a risk that tetanus-toxoid-containing vaccines could cause Guillain-Barré syndrome and, if so, how large the risk is.Missing: diphtheria | Show results with:diphtheria
[103]
Contraindications and Precautions | Vaccines & Immunizations - CDC
Jul 25, 2024 · A vaccine should not be administered when a contraindication is present; for example, MMR vaccine should not be administered to severely immunocompromised ...